Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based, non-randomised clinical trial from Kandahar, Afghanistan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based, non-randomised clinical trial from Kandahar, Afghanistan

Published:2024-05 Issue:5 Volume:63 Page:2400436
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Mesic Anita,Decuyper Ine^ORCID,Ishaq Sadiqqullah,Azizi Taiba,Ziamal Fazal Hadi,Amiri Shirbaz,Keus Kees,Thandar Pyae Moe,Mangal Khan Mohammed,Amirzada Hashim Khan,Rasooli Assadullah,Aloudal Mohammad Reza,Daldar Mohammad Zaher,Decroo Tom^ORCID

Publisher

European Respiratory Society (ERS)

Reference17 articles.

1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

2. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

3. Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

4. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

5. World Health Organization . Rapid Communication: Key Changes to the Treatment of Drug-resistant Tuberculosis. Geneva, World Health Organization, 2022. Report number: WHO/UCN/TB/2022.2.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP